



Renumathy Dhanasekaran

Assistant Professor of Medicine (Gastroenterology)

Medicine - Gastroenterology & Hepatology

CLINICAL OFFICES

- **Division of Abdominal Transplantation**

300 Pasteur Dr A160

Stanford, CA 94305

Tel (650) 498-7878

Fax (650) 498-7888

Bio

BIO

Renumathy Dhanasekaran MD is an Assistant Professor in the Division of Gastroenterology and Hepatology at the School of Medicine, Stanford University. Her primary research goal is to explore the molecular biology of liver cancer in order to identify novel biomarkers and molecular-targeted therapies. She conducts basic and translational research to understand the molecular mechanisms of liver cancer metastasis and dormancy using mouse models of liver cancer. Also, she plays an active role in the cancer genome atlas (TCGA) consortium effort to translate the knowledge gained from the study of genomics of liver cancer. She maintains a biorepository of tissue and blood samples from patients with liver cancer and has also developed several patient derived xenograft (PDX) models for preclinical testing. Dr. Dhanasekaran is a recipient of the American College of Gastroenterology (ACG) Junior Faculty Career Development award and the NIH/NCI K08 career development award.

Dr. Dhanasekaran completed her medical school training in India, and pursued her Internal Medicine residency at the University of Florida, Gainesville followed by Gastroenterology fellowship at Mayo Clinic, Rochester and Transplant Hepatology fellowship at Stanford University. Dr. Dhanasekaran is board certified in Internal Medicine and Gastroenterology. Her clinical practice is mainly focused on liver cancer and she runs a clinic specifically for patients with liver masses.

Lab Website <https://med.stanford.edu/dhanasekaran-lab.html>

CLINICAL FOCUS

- Liver cancer
- Liver transplant
- Hepatology
- Gastroenterology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Gastroenterology & Hepatology

ADMINISTRATIVE APPOINTMENTS

- Member, Stanford Cancer Institute (SCI), Cancer Therapeutics Research Program, (2021- present)
- Associate Member, Canary Center at Stanford, (2021- present)
- Working Group member, CCG Tumor Molecular Pathology (TMP) Analysis Working Group, (2017- present)
- Media Spokesperson, American Gastroenterological Association (AGA), (2016- present)
- Member and Manuscript Co-ordinator, Analysis Working Group, The Cancer Genome Atlas (TCGA), Liver Cancer, (2014-2017)
- Working group Member, AGA Young Delegates Program, (2016-2018)

HONORS AND AWARDS

- AGA-AASLD MasterClass 2018- Selected to attend, AGA/AASLD (Nov 2018)
- 2018 Academic Skills Workshop- Selected to Attend, AGA/AASLD (March 2018)
- 2015 William H. Summerskill award for outstanding achievement in research, Mayo Clinic, Rochester (June 2015)
- Nominated for Edward C. Rosenow II award for Outstanding Trainee Teaching Award, Mayo Clinic, Rochester (June 2015)
- 2016 AGA Women's Leadership Program- Selected to Attend, AGA (Feb 2016)
- Travel Bursary to present abstract, EASL HCC SUMMIT Geneva, Switzerland, (Feb 2014)
- Travel Bursary to present at the Basic science session, ILCA Liver Meeting, Austria (April 2015)
- B Braun Medical Trust Foundation Scholarship, B Braun (2007)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, National Liver Cancer Review Board (2019 - present)
- Member, AASLD Communications Subcommittee (2018 - present)
- Member, AASLD Hepatobiliary neoplasia Special Interest Group (SIG) (2017 - present)
- Member, AGA Research Advocacy Subcommittee (2016 - present)
- Member, AGA Practice management and Economics Committee (2016 - 2017)
- Member, AGA Young GI and Trainee Committee (2015 - 2017)

MEMBERSHIP ORGANIZATIONS

- American Association of the Study of Liver Diseases (AASLD), Member
- American Gastroenterology Association (AGA), Member
- American College of Gastroenterology (ACG), Member

PROFESSIONAL EDUCATION

- Fellowship: Mayo Clinic Gastroenterology Fellowship (2015) MN
- Residency: University of Florida Internal Medicine Residency (2012) FL
- Board Certification: Gastroenterology, American Board of Internal Medicine (2015)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2012)
- Fellowship: Stanford University Gastroenterology Fellowship (2016) CA
- MD, Madras Medical College , Internal Medicine (2008)
- Medical Education: Bangalore Medical College (2005) India

Research & Scholarship

RESEARCH INTERESTS

- Data Sciences
- Leadership and Organization
- Professional Development
- Research Methods
- Science Education

CURRENT RESEARCH AND SCHOLARLY INTERESTS

The overall goal of my research is to understand the molecular pathogenesis of liver cancer and identify biologically relevant prognostic biomarkers and molecular targets for therapy in patients with hepatocellular carcinoma (HCC).

My current ongoing projects focus on these areas-

1. Drivers of tumor dormancy and recurrence of hepatocellular carcinoma (HCC)
2. Drivers of metastatic tumor progression in HCC
3. Prognostic gene signature for HCC
4. Glycoproteomic biomarkers of HCC
5. Using tumor cell free DNA (cfDNA) as biomarkers for HCC
6. Tumor progression of HCC in non alcoholic steatohepatitis (NASH)

CURRENT CLINICAL INTERESTS

- Liver cancer
- Liver transplant
- Non alcoholic steatohepatitis (NASH)
- Benign Liver Lesions

CLINICAL TRIALS

- COVID-19 in Patients With Chronic Liver Diseases, Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Lea Lemaitre, Reshma Reguram

Postdoctoral Research Mentor

Lea Lemaitre

Publications

PUBLICATIONS

- **Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making.** *Hepatology (Baltimore, Md.)*
Dhanasekaran, R., Suzuki, H., Lemaitre, L., Kubota, N., Hoshida, Y.
2023

- **MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.** *Proceedings of the National Academy of Sciences of the United States of America*
Smith, B. A., Deutzmann, A., Correa, K. M., Delaveris, C. S., Dhanasekaran, R., Dove, C. G., Sullivan, D. K., Wisnovsky, S., Stark, J. C., Pluvinaige, J. V., Swaminathan, S., Riley, N. M., Rajan, et al
2023; 120 (11): e2215376120
- **Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study.** *Hepatology communications*
Aby, E. S., Moafa, G., Latt, N., Sultan, M. T., Cacioppo, P. A., Kumar, S., Chung, R. T., Bloom, P. P., Gustafson, J., Daidone, M., Reinus, Z., Debes, J. D., Sandhu, et al
2023; 7 (1): e8874
- **MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma that is Reversible Through Restoration of Pro-Inflammatory Macrophages.** *Cancer research*
Dhanasekaran, R., Hansen, A. S., Park, J., Lemaitre, L., Lai, I., Adeniji, N., Kuruvilla, S., Suresh, A., Zhang, J., Swamy, V., Felsher, D. W.
2022
- **MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.** *Oncogene*
Sullivan, D. K., Deutzmann, A., Yarbrough, J., Krishnan, M. S., Gouw, A. M., Bellovin, D. I., Adam, S. J., Liefwalker, D. F., Dhanasekaran, R., Felsher, D. W.
2022
- **SPATIAL MULTI-OMIC IMMUNE PROFILING AND FUNCTIONAL CHARACTERIZATION OF HEPATOCELLULAR CARCINOMA (HCC) REVEAL MECHANISMS OF MINIMAL RESIDUAL DISEASE (MRD)**
Suresh, A., Adeniji, N., Lemaitre, L., Charu, V., Dhanasekaran, R.
WILEY.2022: S1278
- **SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis.** *Journal of autoimmunity*
Efe, C., Tascilar, K., Gerussi, A., Bolis, F., Lammert, C., Ebik, B., Stattermayer, A. F., Cengiz, M., Gokce, D. T., Cristoferi, L., Peralta, M., Massoumi, H., Montes, et al
2022; 132: 102906
- **Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites.** *BMC gastroenterology*
Alshwaykh, O., Cheung, A., Goel, A., Kwong, A., Dhanasekaran, R., Ghaziani, T. T., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Nguyen, M., Kim, W. R., Kwo, et al
2022; 22 (1): 410
- **Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.** *Hepatology communications*
Alshwaykh, O., Daugherty, T., Cheung, A., Goel, A., Dhanasekaran, R., Ghaziani, T. T., Ahmed, A., Dronamraju, D., Kumari, R., Kwong, A., Nguyen, M., Kim, W. R., Kwo, et al
2022
- **SPATIAL TRANSCRIPTOMIC CHARACTERIZATION OF HEPATOCELLULAR CARCINOMA (HCC) REVEALS PREDICTIVE BIOMARKERS AND MOLECULAR TARGETS OF RECURRENCE**
Suresh, A., Adeniji, N., Lemaitre, L., Kolahi, K., Kambham, N., Charu, V., Dhanasekaran, R.
W B SAUNDERS CO-ELSEVIER INC.2022: S1123-S1124
- **Implications of genetic heterogeneity in hepatocellular cancer.** *Advances in cancer research*
Suresh, A., Dhanasekaran, R.
2022; 156: 103-135
- **Treacherous apoptosis- cancer cells sacrifice themselves at the altar of heterogeneity.** *Hepatology (Baltimore, Md.)*
Dhanasekaran, R.
2022
- **Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis.** *Liver international : official journal of the International Association for the Study of the Liver*
Efe, C., Lammert, C., Tascilar, K., Dhanasekaran, R., Ebik, B., Higuera-de la Tijera, F., Caliskan, A. R., Peralta, M., Gerussi, A., Massoumi, H., Catana, A. M., Purnak, T., Rigamonti, et al
2021
- **THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS WITH CIRRHOSIS NOT MEETING CURRENT TREATMENT GUIDANCE**

- Alshuwaykh, O., Goel, A., Ghaziani, T., Daugherty, T., Dhanasekaran, R., Ahmed, A., Dronamraju, D., Kwong, A. J., Nguyen, M. H., Cheung, A., Kwo, P.
WILEY.2021: 500A-501A
- **LONG-TERM CLINICAL OUTCOMES OF PATIENTS WITH COVID-19 AND CHRONIC LIVER DISEASE: US MULTICENTER STUDY COLD STUDY**
Aby, E., Gustafson, J. L., Daidone, M., Chung, R. T., Sandhu, S., Sohal, A., Khalid, S., Roytman, M., Varelas, L., Moghe, A., Moafa, G., Latt, N. L., Carr, et al
WILEY.2021: 48A-49A
 - **DISTINCT IMMUNE MECHANISMS OF COMBINED PD-L1 AND CTLA-4 BLOCKADE IN HEPATOCELLULAR CARCINOMA (HCC)**
Dhanasekaran, R., Hansen, A., Park, J., Lai, I., Adeniji, N., Kuruvilla, S., Felsher, D.
WILEY.2021: 110A
 - **Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge** *WORLD JOURNAL OF HEPATOLOGY*
Mattos, A. Z., Debes, J. D., Dhanasekaran, R., Benhammou, J. N., Arrese, M., Patricio, A., Zilio, A. C., Mattos, A. A.
2021; 13 (9): 1107-1121
 - **Current and Emerging Tools for Hepatocellular Carcinoma Surveillance.** *Hepatology communications*
Adeniji, N., Dhanasekaran, R.
2021
 - **The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.** *Nature reviews. Clinical oncology*
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., Felsher, D. W.
2021
 - **Screening for Hepatocellular Carcinoma in Patients with Hepatitis B.** *Viruses*
Sachar, Y., Brahmania, M., Dhanasekaran, R., Congly, S. E.
2021; 13 (7)
 - **Screening for Hepatocellular Carcinoma in Patients with Hepatitis B** *VIRUSES-BASEL*
Sachar, Y., Brahmania, M., Dhanasekaran, R., Congly, S. E.
2021; 13 (7)
 - **Outcomes of Downstaging Hepatocellular Carcinoma (HCC) to within Milan Criteria Before Liver Transplantation (LT): A Multicenter Analysis of the "All-comers" Protocol**
Natarajan, B., Tabrizian, P., Hoteit, M., Frenette, C., Ghaziani, T., Dhanasekaran, R., Parikh, N., Guy, J., Shui, A., Florman, S., Yao, F., Mehta, N.
WILEY.2021: 324
 - **Outcome of COVID-19 in Patients with Autoimmune Hepatitis: an International Multi-Centre Study.** *Hepatology (Baltimore, Md.)*
Efe, C., Dhanasekaran, R., Lammert, C., Ebi, B., Higuera-de la Tijera, F., Aloman, C., Riza Caliskan, A., Peralta, M., Gerussi, A., Massoumi, H., Catana, A. M., Torgutalp, M., Purnak, et al
2021
 - **Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation.** *Hepatology communications*
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Kim, W. R., Nguyen, M. H., Esquivel, C. O., Concepcion, et al
2021; 5 (3): 516-525
 - **Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat.** *Clinical liver disease*
Dhanasekaran, R., Kwo, P. Y.
2021; 17 (3): 169-73
 - **Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)-Multi-Omic and Singulomic Approaches** *SEMINARS IN LIVER DISEASE*
Dhanasekaran, R.
2021
 - **Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)-Multi-Omic and Singulomic Approaches.** *Seminars in liver disease*
Dhanasekaran, R.
2021; 41 (1): 9-18
 - **Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.** *Human pathology*
Torbenson, M., McCabe, C. E., O'Brien, D. R., Yin, J., Bainter, T., Tran, N. H., Yasir, S., Chen, Z. E., Dhanasekaran, R., Ahn, K. S., Roberts, L. R., Wang, C.

2021; 119: 15-27

- **Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).** *Current Treatment Options in Gastroenterology*
Ghaziani, T., Dhanasekaran, R.
2021; 19 (1): 351–368
- **Down-staging Outcomes for Hepatocellular Carcinoma: Results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.** *Gastroenterology*
Mehta, N., Frenette, C., Tabrizian, P., Hoteit, M., Guy, J., Parikh, N., Ghaziani, T. T., Dhanasekaran, R., Dodge, J. L., Natarajan, B., Holzner, M. L., Frankul, L., Chan, et al
2021
- **Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation** *HEPATOLOGY COMMUNICATIONS*
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Kim, W., Esquivel, C. O., Concepcion, W., Melcher, et al
2020
- **Genomic Landscape of HCC.** *Current hepatology reports*
Nia, A., Dhanasekaran, R.
2020; 19 (4): 448–61
- **Socioeconomic Factors Contribute to the Higher Risk of COVID-19 in Racial and Ethnic Minorities with Chronic Liver Diseases (CLD).** *Gastroenterology*
Adeniji, N., Carr, R. M., Aby, E. S., Catana, A. M., Wegermann, K., Dhanasekaran, R.
2020
- **THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS NOT MEETING CRITERIA FOR ANTIVIRAL THERAPY**
Alshuwaykh, O., Goel, A., Daugherty, T., Cheung, A., Kim, W., Kwong, A. J., Ahmed, A., Ghaziani, T., Torok, N. J., Nguyen, M. H., Dronamraju, D., Dhanasekaran, R., Kumari, et al
WILEY.2020: 472A–473A
- **PATTERNS AND PREDICTORS OF LIVER INJURY IN LIVER TRANSPLANT RECIPIENTS WITH CORONAVIRUS DISEASE 2019 (COVID-19)**
Rabiee, A., Sadowski, B., Adeniji, N., Nguyen, V., Moghe, A., Perumalswami, P. V., Lett, N. L., Kumar, S., Aloman, C., Catana, M., Bloom, P. P., Chavin, K. D., Carr, et al
WILEY.2020: 295A
- **PREDICTORS OF OUTCOMES OF COVID-19 IN PATIENTS WITH CHRONIC LIVER DISEASE: US MULTI-CENTER STUDY**
Adeniji, N., Kim, D., Latt, N. L., Kumar, S., Bloom, P. P., Aby, E. S., Perumalswami, P. V., Roytman, M., Li, M., Vogel, A. S., Catana, A. M., Wegermann, K., Carr, et al
WILEY.2020: 7A
- **Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study.** *Journal of hepatology*
Marjot, T., Moon, A. M., Cook, J. A., Abd-Elsalam, S., Aloman, C., Armstrong, M. J., Pose, E., Brenner, E. J., Cargill, T., Catana, M., Dhanasekaran, R., Eshraghian, A., Garcia-Juarez, et al
2020
- **Characterizing Ascites in Subjects With Nonhepatic Solid Tumors**
Alshuwaykh, O., Cheung, A., Goel, A., Dhanasekaran, R., Ahmed, A., Dronamraju, D., Daugherty, T., Kim, R. W., Kumari, R., Torok, N., Ghaziani, T., Kwo, P. Y.
LIPPINCOTT WILLIAMS & WILKINS.2020: S507
- **Clinical Response to Treatment for Acute Kidney Injury (AKI) in Patients With Cirrhosis**
John, N., Alshuwaykh, O., Goel, A., Ahmed, A., Cheung, A., Dronamraju, D., Kumari, R., Daugherty, T., Dhanasekaran, R., Kim, R. W., Nguyen, M. H., Kwo, P. Y.
LIPPINCOTT WILLIAMS & WILKINS.2020: S587–S588
- **Liver Injury in Liver Transplant Recipients with Coronavirus Disease 2019 (COVID-19): US Multicenter Experience.** *Hepatology (Baltimore, Md.)*
Rabiee, A., Sadowski, B., Adeniji, N., Perumalswami, P., Nguyen, V., Moghe, A., Latt, N., Kumar, S., Aloman, C., Catana, A. M., Bloom, P. P., Chavin, K., Carr, et al
2020
- **MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC** *MOLECULAR THERAPY-NUCLEIC ACIDS*

- Dhanasekaran, R., Park, J., Yevtdiyenko, A., Bellocin, D. I., Adam, S. J., Rajan, A., Gabay, M., Fernando, H., Arzeno, J., Arjunan, V., Gryanzov, S., Felsher, D. W.
2020; 21: 850–59
- **Roadmap to Resuming Care for Liver Diseases after COVID-19.** *Journal of gastroenterology and hepatology*
Kapuria, D., Bollipo, S., Rabiee, A., Ben Yakov, G., Kumar, G., Siau, K., Lee, H., Congly, S., Turnes, J., Dhanasekaran, R., Lui, R. N., Global Online Alliance for Liver Studies (GOAL)
2020
 - **MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC.** *Molecular therapy. Nucleic acids*
Dhanasekaran, R., Park, J., Yevtdiyenko, A., Bellocin, D. I., Adam, S. J., Kd, A. R., Gabay, M., Fernando, H., Arzeno, J., Arjunan, V., Gryanzov, S., Felsher, D. W.
2020; 21: 850–59
 - **MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.** *Nature communications*
Swaminathan, S., Hansen, A. S., Heftdal, L. D., Dhanasekaran, R., Deutzmann, A., Fernandez, W. D., Liefwalker, D. F., Horton, C., Mosley, A., Liebersbach, M., Maecker, H. T., Felsher, D. W.
2020; 11 (1): 2860
 - **One world, one pandemic, many guidelines: management of liver diseases during COVID-19.** *Gut*
Bollipo, S., Kapuria, D., Rabiee, A., Ben-Yakov, G., Lui, R. N., Lee, H. W., Kumar, G., Siau, K., Turnes, J., Dhanasekaran, R.
2020
 - **Decline in Annual Mortality of Hepatitis C Virus-related Hepatocellular Carcinoma in the United States, From 2009 to 2018.** *Gastroenterology*
Kim, D., Konyon, P., Cholankeril, G., Wong, R. J., Younossi, Z. M., Ahmed, A.
2020
 - **Transarterial Chemoembolization and Radio-Embolization are Similarly Efficacious in Achieving Successful Hepatocellular Carcinoma (HCC) Down-Staging: Results from the Multicenter Evaluation of Reduction in Tumor Size Before Liver Transplantation (MERITS-LT) Consortium**
Mehta, N., Guy, J., Frenette, C., Tabrizian, P., Hoteit, M., Parikh, N., Ghaziani, T., Dhanasekaran, R., Dodge, J. L., Holzner, M. L., Florman, S., Yao, F.
WILEY.2020: 489
 - **MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity.** *eLife*
Dhanasekaran, R., Baylot, V., Kim, M., Kuruvilla, S., Bellocin, D. I., Adeniji, N., Rajan Kd, A., Lai, I., Gabay, M., Tong, L., Krishnan, M., Park, J., Hu, et al
2020; 9
 - **Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Kim, D. n., Adeniji, N. n., Latt, N. n., Kumar, S. n., Bloom, P. P., Aby, E. S., Perumalswami, P. n., Roytman, M. n., Li, M. n., Vogel, A. S., Catana, A. M., Wegermann, K. n., Carr, et al
2020
 - **Spontaneous Regression of HCC- When the Immune System Stands Up to Cancer.** *Hepatology (Baltimore, Md.)*
Arjunan, V. n., Hansen, A. n., Deutzmann, A. n., Sze, D. Y., Dhanasekaran, R. n.
2020
 - **Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers.** *Hepatology (Baltimore, Md.)*
Krishnan, M. S., Rajan Kd, A. n., Park, J. n., Arjunan, V. n., Garcia Marques, F. J., Bermudez, A. n., Girvan, O. A., Hoang, N. S., Yin, J. n., Nguyen, M. H., Kothary, N. n., Pitteri, S. n., Felsher, et al
2020
 - **Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.** *The lancet. Gastroenterology & hepatology*
Webb, G. J., Marjot, T. n., Cook, J. A., Aloman, C. n., Armstrong, M. J., Brenner, E. J., Catana, M. A., Cargill, T. n., Dhanasekaran, R. n., García-Juárez, I. n., Hagström, H. n., Kennedy, J. M., Marshall, et al
2020
 - **Post-Transplant Outcomes in Older Patients with Hepatocellular Carcinoma (HCC) are Driven by non-HCC Factors.** *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*
Adeniji, N. n., Arjunan, V. n., Prabhakar, V. n., Mannalithara, A. n., Ghaziani, T. n., Ahmed, A. n., Kwo, P. n., Nguyen, M. n., Melcher, M. L., Busuttil, R. W., Florman, S. S., Haydel, B. n., Ruiz, et al

2020

- **High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry.** *Journal of hepatology*
Moon, A. M., Webb, G. J., Aloman, C. n., Armstrong, M. J., Cargill, T. n., Dhanasekaran, R. n., Genescà, J. n., Gill, U. S., James, T. W., Jones, P. D., Marshall, A. n., Mells, G. n., Perumalswami, et al
2020
- **Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-Transplant Clinical Outcome.** *Clinical transplantation*
Adeniji, N. n., Arjunan, V. n., Prabhakar, V. n., Tulu, Z. n., Kambham, N. n., Ahmed, A. n., Kwo, P. n., Dhanasekaran, R. n.
2020: e14128
- **MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T-Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling**
Swaminathan, S., Heftdal, L., Liefwalker, D., Dhanasekaran, R., Deutzmann, A., Horton, C., Mosley, A., Liebersbach, M., Gentles, A., Maecker, H. T., Felsher, D.
AMER SOC HEMATOLOGY.2019
- **DIRECT-ACTING ANTIVIRAL THERAPY IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH A HISTORY OF HEPATOCELLULAR CARCINOMA: A MULTICENTER NORTH AMERICAN COHORT STUDY**
Singal, A. G., Rich, N. E., Mehta, N., Branch, A. D., Pillai, A. A., Hoteit, M. A., Volk, M., Odewole, M., Scaglione, S. J., Guy, J. E., Said, A., Feld, J. J., John, et al
WILEY.2019: 130A–131A
- **CROSS-SPECIES COMPREHENSIVE PROTEOMIC ANALYSIS OF HEPATOCELLULAR CARCINOMA (HCC) TO IDENTIFY PLASMA BIOMARKERS OF VASCULAR INVASION**
Krishnan, M., Arjunan, V., Kothary, N., Felsher, D., Dhanasekaran, R.
WILEY.2019: 74A
- **THE ROLE OF LOCOREGIONAL THERAPY (LRT), POST LRT IMAGING, AND EXPLANT PATHOLOGY AS PREDICTORS OF HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANT (OLT)**
Prabhakar, V., Dhanasekaran, R., Arjunan, V., Tulu, Z., Ahmed, A., Daugherty, T., Kumari, R., Patel, B., Kim, W., Goel, A., Esquivel, C. O., Concepcion, W., Melcher, et al
WILEY.2019: 691A–692A
- **IS IT GOOD IDEA TO OFFER TRANSPLANT EXCEPTION POINTS FOR SEPTUAGENARIANS WITH HEPATOCELLULAR CARCINOMA (HCC)?**
Arjunan, V., Prabhakar, V., Raghavan, S., Tulu, Z., Kambham, N., Ahmed, A., Kwo, P., Dhanasekaran, R.
WILEY.2019: 557A–558A
- **CLINICOPATHOLOGICAL FEATURES OF NONALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC)**
Arjunan, V., Prabhakar, V., Raghavan, S., Tulu, Z., Kambham, N., Ahmed, A., Kwo, P., Dhanasekaran, R.
WILEY.2019: 548A
- **A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma** *HEPATOLOGY*
Dhanasekaran, R., Felsher, D. W.
2019; 70 (3): 1056–58
- **The Immune Landscape of Cancer.** *Immunity*
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., Ziv, E., Culhane, A. C., Paull, et al
2019; 51 (2): 411–12
- **A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC).** *Hepatology (Baltimore, Md.)*
Dhanasekaran, R., Felsher, D. W.
2019
- **Prospective Multi-Regional Study of Down-Staging of Hepatocellular Carcinoma to within Milan Criteria before Liver Transplantation.**
Mehta, N., Guy, J., Frenette, C., Tabrizian, P., Hoteit, M., Dhanasekaran, R., Dodge, J., Holzner, M. L., Frankul, L., Florman, S., Parikh, N., Yao, F.
WILEY.2019: 378–79
- **Hepatocellular Carcinoma Surveillance: An Effective But Complex Process** *GASTROENTEROLOGY*
Singal, A. G., Murphy, C. C.

2019; 156 (4): 1215

- **Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma.** *Gastroenterology*
Singal, A. G., Rich, N. E., Mehta, N. n., Branch, A. n., Pillai, A. n., Hoteit, M. n., Volk, M. n., Odewole, M. n., Scaglione, S. n., Guy, J. n., Said, A. n., Feld, J. J., John, et al
2019
- **Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.** *Gastroenterology*
Singal, A. G., Rich, N. E., Mehta, N. n., Branch, A. n., Pillai, A. n., Hoteit, M. n., Volk, M. n., Odewole, M. n., Scaglione, S. n., Guy, J. n., Said, A. n., Feld, J. J., John, et al
2019; 156 (6): 1683–92.e1
- **Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy** *GASTROENTEROLOGY*
Dhanasekaran, R., Nault, J., Roberts, L. R., Zucman-Rossi, J.
2019; 156 (2): 492–509
- **Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Rich, N. E., Yang, J. D., Perumalswami, P. V., Alkhoury, N. n., Jackson, W. n., Parikh, N. D., Mehta, N. n., Salgia, R. n., Duarte-Rojo, A. n., Kulik, L. n., Rakoski, M. n., Said, A. n., Oloruntoba, et al
2019
- **MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies**
Swaminathan, S., Heftdal, L., Liefwalker, D. F., Dhanasekaran, R., Deutzmann, A., Horton, C., Mosley, A., Liebersbach, M., Maecker, H. T., Felsher, D.
AMER SOC HEMATOLOGY.2018
- **Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*
Lai, I., Swaminathan, S., Baylot, V., Mosley, A., Dhanasekaran, R., Gabay, M., Felsher, D. W.
2018; 6
- **Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma.** *Journal for immunotherapy of cancer*
Lai, I., Swaminathan, S., Baylot, V., Mosley, A., Dhanasekaran, R., Gabay, M., Felsher, D. W.
2018; 6 (1): 125
- **Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.** *Gastroenterology*
Dhanasekaran, R., Nault, J., Roberts, L. R., Zucman-Rossi, J.
2018
- **Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer** *CELL REPORTS*
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P., Jeong, K., Tsang, Y., Moreno, D., Bhavana, V., Peng, X., Ge, Z., Chen, et al
2018; 25 (5): 1304+
- **Direct-Acting Antiviral Therapy Significantly Reduces Early HCC Recurrence: A Multicenter US Cohort Study**
Singal, A. G., Mehta, N., Rich, N. E., Murphy, C., Branch, A. D., Pillai, A. A., Hoteit, M. A., Volk, M., Odewole, M., Scaglione, S. J., Guy, J. E., Said, A., Feld, et al
WILEY.2018: 58A–59A
- **Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients** *CANCER CELL*
Kahles, A., Lehmann, K., Toussaint, N. C., Huser, M., Stark, S. G., Sachsenberg, T., Stegle, O., Kohlbacher, O., Sander, C., Ratsch, G., Canc Genome Atlas Res Network
2018; 34 (2): 211+
- **Comprehensive Characterization of Cancer Driver Genes and Mutations (vol 173, 371.e1, 2018)** *CELL*
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., Ng, P., Jeong, K., Cao, et al
2018; 174 (4): 1034-1035

- **The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (vol 23, pg 313, 2018)** *CELL REPORTS*
Ricketts, C. J., De Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., Bottaro, D. P., Choueiri, T. K., Gibbs, et al
2018; 23 (12): 3698
- **The Immune Landscape of Cancer** *IMMUNITY*
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Yang, T., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., Ziv, E., Culhane, A. C., Paull, et al
2018; 48 (4): 812-+
- **Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas** *CANCER CELL*
Liu, Y., Sethi, N. S., Hinoue, T., Schneider, B. G., Cherniack, A. D., Sanchez-Vega, F., Seoane, J. A., Farshidfar, F., Bowlby, R., Islam, M., Kim, J., Chatila, W., Akbani, et al
2018; 33 (4): 721-+
- **Genomic and Functional Approaches to Understanding Cancer Aneuploidy** *CANCER CELL*
Taylor, A. M., Shih, J., Ha, G., Gao, G. F., Zhang, X., Berger, A. C., Schumacher, S. E., Wang, C., Hu, H., Liu, J., Lazar, A. J., Cherniack, A. D., Beroukhim, et al
2018; 33 (4): 676-+
- **lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer** *CANCER CELL*
Wang, Z., Yang, B., Zhang, M., Guo, W., Wu, Z., Wang, Y., Jia, L., Li, S., Xie, W., Yang, D., Canc Genome Atlas Res Network
2018; 33 (4): 706-+
- **Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation** *CELL*
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kaminska, B., Huelsken, J., Omberg, L., Gevaert, O., Colaprico, A., Czerwinska, P., Mazurek, et al
2018; 173 (2): 338-+
- **Comprehensive Characterization of Cancer Driver Genes and Mutations** *CELL*
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., Ng, P., Jeong, K., Cao, et al
2018; 173 (2): 371-+
- **Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics** *CELL*
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K., Tokheim, C., Cortes-Ciriano, I., Jayasinghe, R., Chen, et al
2018; 173 (2): 305-+
- **A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples** *CELL*
Chen, H., Li, C., Peng, X., Zhou, Z., Weinstein, J. N., Liang, H., Canc Genome Atlas Res Network
2018; 173 (2): 386-+
- **Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer** *CELL*
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., Akbani, R., Bowlby, R., Wong, et al
2018; 173 (2): 291-+
- **An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics** *CELL*
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., Omberg, L., Wolf, D. M., Shriver, et al
2018; 173 (2): 400-+
- **Oncogenic Signaling Pathways in The Cancer Genome Atlas** *CELL*
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghaifinia, S., Chakravarty, D., Daian, F., Gao, et al
2018; 173 (2): 321-+
- **Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas** *CELL REPORTS*
Campbell, J. D., Yau, C., Bowlby, R., Liu, Y., Brennan, K., Fan, H., Taylor, A. M., Wang, C., Walter, V., Akbani, R., Byers, L., Creighton, C. J., Coarfa, et al
2018; 23 (1): 194-+

- **Driver Fusions and Their Implications in the Development and Treatment of Human Cancers** *CELL REPORTS*
Gao, Q., Liang, W., Foltz, S. M., Mutharasu, G., Jayasinghe, R. G., Cao, S., Liao, W., Reynolds, S. M., Wyczalkowski, M. A., Yao, L., Yu, L., Sun, S. Q., Chen, et al
2018; 23 (1): 227-+
- **Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types** *CELL REPORTS*
Ge, Z., Leighton, J. S., Wang, Y., Peng, X., Chen, Z., Chen, H., Sun, Y., Yao, F., Li, J., Zhang, H., Liu, J., Shriver, C. D., Hu, et al
2018; 23 (1): 213-+
- **Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context** *CELL REPORTS*
Chiu, H., Somvanshi, S., Patel, E., Chen, T., Singh, V. P., Zorman, B., Patil, S. L., Pan, Y., Chatterjee, S. S., Sood, A. K., Gunaratne, P. H., Sumazin, P., Canc Genome Atlas Res Network
2018; 23 (1): 297-+
- **Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types** *CELL REPORTS*
Seiler, M., Peng, S., Agrawal, A. A., Palacino, J., Teng, T., Zhu, P., Smith, P. G., Buonamici, S., Yu, L., Canc Genome Atlas Res Network
2018; 23 (1): 282-+
- **Systematic Analysis of Splice-Site-Creating Mutations in Cancer** *CELL REPORTS*
Jayasinghe, R. G., Cao, S., Gao, Q., Wendl, M. C., Vo, N., Reynolds, S. M., Zhao, Y., Climente-Gonzalez, H., Chai, S., Wang, F., Varghese, R., Huang, M., Liang, et al
2018; 23 (1): 270-+
- **Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas** *CELL REPORTS*
Way, G. P., Sanchez-Vega, F., La, K., Armenia, J., Chatila, W. K., Luna, A., Sander, C., Cherniack, A. D., Mina, M., Ciriello, G., Schultz, N., Sanchez, Y., Greene, et al
2018; 23 (1): 172-+
- **Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images** *CELL REPORTS*
Saltz, J., Gupta, R., Hou, L., Kurc, T., Singh, P., Vu Nguyen, Samaras, D., Shroyer, K. R., Zhao, T., Batiste, R., Van Arnam, J., Shmulevich, I., Rao, A. K., et al
2018; 23 (1): 181-+
- **Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas** *CELL REPORTS*
Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., Liu, Y., Akbani, R., Feng, et al
2018; 23 (1): 239-+
- **Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas** *CELL SYSTEMS*
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., Ayer, D. E., Hurlin, P. J., Cherniack, et al
2018; 6 (3): 282-+
- **Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines** *CELL SYSTEMS*
Ellrott, K., Bailey, M. H., Saksena, G., Covington, K. R., Kandath, C., Stewart, C., Hess, J., Ma, S., Chiotti, K. E., McLellan, M., Sofia, H. J., Hutter, C., Getz, et al
2018; 6 (3): 271-+
- **Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/ β -catenin-induced FGF18 expression in hepatocellular carcinoma.** *Oncogene*
Guo, P. n., Wang, Y. n., Dai, C. n., Tao, C. n., Wu, F. n., Xie, X. n., Yu, H. n., Zhu, Q. n., Li, J. n., Ye, L. n., Yu, F. n., Shan, Y. n., Yu, et al
2018; 37 (9): 1220–36
- **Pathogenic Germline Variants in 10,389 Adult Cancers.** *Cell*
Huang, K. L., Mashl, R. J., Wu, Y. n., Ritter, D. I., Wang, J. n., Oh, C. n., Paczkowska, M. n., Reynolds, S. n., Wyczalkowski, M. A., Oak, N. n., Scott, A. D., Krassowski, M. n., Cherniack, et al
2018; 173 (2): 355–70.e14
- **A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.** *Cancer cell*
Berger, A. C., Korkut, A. n., Kanchi, R. S., Hegde, A. M., Lenoir, W. n., Liu, W. n., Liu, Y. n., Fan, H. n., Shen, H. n., Ravikumar, V. n., Rao, A. n., Schultz, A. n., Li, et al
2018; 33 (4): 690–705.e9
- **A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily.** *Cell systems*

- Korkut, A. n., Zaidi, S. n., Kanchi, R. S., Rao, S. n., Gough, N. R., Schultz, A. n., Li, X. n., Lorenzi, P. L., Berger, A. C., Robertson, G. n., Kwong, L. N., Datto, M. n., Roszik, et al
2018; 7 (4): 422–37.e7
- **The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.** *Cell reports*
Ricketts, C. J., De Cubas, A. A., Fan, H. n., Smith, C. C., Lang, M. n., Reznik, E. n., Bowlby, R. n., Gibb, E. A., Akbani, R. n., Beroukhim, R. n., Bottaro, D. P., Choueiri, T. K., Gibbs, et al
2018; 23 (1): 313–26.e5
 - **Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.** *Cell reports*
Peng, X. n., Chen, Z. n., Farshidfar, F. n., Xu, X. n., Lorenzi, P. L., Wang, Y. n., Cheng, F. n., Tan, L. n., Mojumdar, K. n., Du, D. n., Ge, Z. n., Li, J. n., Thomas, et al
2018; 23 (1): 255–69.e4
 - **Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).** *Oncotarget*
Dhanasekaran, R. n., Gabay-Ryan, M. n., Baylot, V. n., Lai, I. n., Mosley, A. n., Huang, X. n., Zabudoff, S. n., Li, J. n., Kaimal, V. n., Karmali, P. n., Felsher, D. W.
2018; 9 (5): 5517–28
 - **YAP-associated chromosomal instability and cholangiocarcinoma in mice.** *Oncotarget*
Rizvi, S. n., Fischbach, S. R., Bronk, S. F., Hirsova, P. n., Krishnan, A. n., Dhanasekaran, R. n., Smadbeck, J. B., Smoot, R. L., Vasmatzis, G. n., Gores, G. J.
2018; 9 (5): 5892–5905
 - **MYC functions as a master switch for natural killer cell-mediated immune surveillance of lymphoid malignancies**
Swaminathan, S., Mosley, A., Horton, C., Liefwalker, D. F., Deutzmann, A., Dhanasekaran, R., Gouw, A., Gentles, A., Eilers, M., Maecker, H. T., Felsher, D. W.
AMER ASSOC CANCER RESEARCH.2017
 - **Management of Immunosuppression in Liver Transplantation** *CLINICS IN LIVER DISEASE*
Dhanasekaran, R.
2017; 21 (2): 337-?
 - **Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.** *Cardiovascular and interventional radiology*
Xing, M., Sakaria, S., Dhanasekaran, R., Parekh, S., Spivey, J., Knechtle, S. J., Zhang, D., Kim, H. S.
2017; 40 (3): 410-420
 - **Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.** *American journal of clinical oncology*
Xing, M., Prajapati, H. J., Dhanasekaran, R., Lawson, D. H., Kokabi, N., Eaton, B. R., Kim, H. S.
2017; 40 (1): 27-34
 - **Transcriptional Induction of Periostin by a Sulfatase 2-TGF beta 1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma** *CANCER RESEARCH*
Chen, G., Nakamura, I., Dhanasekaran, R., Iguchi, E., Tolosa, E. J., Romecin, P. A., Vera, R. E., Almada, L. L., Miamen, A. G., Chaiteerakij, R., Zhou, M., Asiedu, M. K., Moser, et al
2017; 77 (3): 632-645
 - **Selective Internal Yttrium-90 Radioembolization Therapy (Y-90-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy Safety and Efficacy Cohort Study** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Xing, M., Prajapat, H. J., Dhanasekaran, R., Lawson, D. H., Kokabi, N., Eaton, B. R., Kim, H. S.
2017; 40 (1): 27-34
 - **Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.** *Cell*
2017; 169 (7): 1327–41.e23
 - **The Liver in Oncology.** *Clinics in liver disease*
Dhanasekaran, R. n., Kwo, P. Y.
2017; 21 (4): 697–707
 - **Differences in Hepatocellular Carcinoma Incidence and Survival Rates among Asian Mono-Ethnicities**

- Cholankeril, G., Perumpail, R. B., Hu, M., Pham, E. A., Kumari, R., Gish, R., So, S. K., Dhanasekaran, R., Ahmed, A.
WILEY.2016: 860A
- **Rising Inpatient Healthcare Resource Utilization in Baby Boomers with Hepatocellular Carcinoma**
Cholankeril, G., Al Juboori, A., Perumpail, R. B., Yoo, E. R., Hu, M., Dhanasekaran, R., Kanwal, F., Ahmed, A.
WILEY.2016: 679A
 - **Identification of Novel Fusions in Gallbladder Cancer by Next Generation Sequencing RNA Analysis - Potential for Targeted Therapy**
Allotey, L. K., Nair, A., Chaiteerakij, R., Oliver, G., O'Brien, D., Sarangi, V., Moser, C. D., Giama, N. H., Dhanasekaran, R., Bonilla, L., Klee, E., Borad, M., Roberts, et al
W B SAUNDERS CO-ELSEVIER INC.2016: S295-S296
 - **Clinical implications of basic research in hepatocellular carcinoma** *JOURNAL OF HEPATOLOGY*
Dhanasekaran, R., Venkatesh, S. K., Torbenson, M. S., Roberts, L. R.
2016; 64 (3): 736-745
 - **Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances.** *F1000Research*
Dhanasekaran, R., Bandoh, S., Roberts, L. R.
2016; 5
 - **Response to Fibrosis progression in patients treated for hepatitis C recurrence** *LIVER INTERNATIONAL*
Dhanasekaran, R., Sanchez, W., Charlton, M.
2015; 35 (12): 2625-2625
 - **Impact of fibrosis progression on clinical outcome in patients treated for post- transplant hepatitis C recurrence** *LIVER INTERNATIONAL*
Dhanasekaran, R., Sanchez, W., Mounajjed, T., Wiesner, R. H., Watt, K. D., Charlton, M. R.
2015; 35 (11): 2433-2441
 - **Multi-platform analysis of Telomerase Reverse Transcriptase (TERT) gene alterations in Hepatocellular Carcinoma (HCC)** *66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)*
Dhanasekaran, R., Covington, K., Watt, J., Cherniack, A. D., O'Brien, D. R., Lee, J., Creighton, C., Munzy, D. M., Roberts, L. R., Wheeler, D. A.
WILEY-BLACKWELL.2015: 274A-275A
 - **Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma.** *Current gastroenterology reports*
Dhanasekaran, R., Talwalkar, J. A.
2015; 17 (9): 34-?
 - **Activation of the Transforming Growth Factor-beta/SMAD Transcriptional Pathway Underlies a Novel Tumor-Promoting Role of Sulfatase 1 in Hepatocellular Carcinoma** *HEPATOLOGY*
Dhanasekaran, R., Nakamura, I., Hu, C., Chen, G., Oseini, A. M., Seven, E. S., Miamen, A. G., Moser, C. D., Zhou, W., van Kuppevelt, T. H., van Deursen, J. M., Mounajjed, T., Fernandez-Zapico, et al
2015; 61 (4): 1269-1283
 - **Vasodilator-Stimulated Phosphoprotein Promotes Activation of Hepatic Stellate Cells by Regulating Rab11-Dependent Plasma Membrane Targeting of Transforming Growth Factor Beta Receptors** *HEPATOLOGY*
Tu, K., Li, J., Verma, V. K., Liu, C., Billadeau, D. D., Lamprecht, G., Xiang, X., Guo, L., Dhanasekaran, R., Roberts, L. R., Shah, V. H., Kang, N.
2015; 61 (1): 361-374
 - **Sulfatase2 (SULF2) Promotes Angiogenesis in Hepatocellular Carcinoma Partly Through the TGF beta 1/Periostin Signaling Pathway**
Chen, G., Miamen, A., Dhanasekaran, R., Moser, C. D., Han, S., Chen, Y., Fang, Y., Yang, D., Shaleh, H. M., Hu, C., Thorgeirsson, S., Roberts, L. R.
W B SAUNDERS CO-ELSEVIER INC.2014: S927-S928
 - **Challenges of recurrent hepatitis C in the liver transplant patient** *WORLD JOURNAL OF GASTROENTEROLOGY*
Dhanasekaran, R., Firpi, R. J.
2014; 20 (13): 3391-3400
 - **A potential role for type XVIII collagen as a suppressor of hepatocellular carcinoma** *65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*
Duncan, M., Dhanasekaran, R., Thakur, P., Roberts, L. R.
WILEY-BLACKWELL.2014: 642A-642A

- **Comparing Internet Search Patterns for Gastroenterological Diagnoses to Physician Visit Data**
Dhanasekaran, R., Oxentenko, A.
NATURE PUBLISHING GROUP.2013: S477
- **Analysis of Paired Biopsies to Assess Progression of Fibrosis in Patients Treated for Post-Transplant Hepatitis C Recurrence** *Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT)*
Dhanasekaran, R., Charlton, M. R., Sanchez, W.
W B SAUNDERS CO-ELSEVIER INC.2013: S1028–S1028
- **Hepatic Preservation Injury: Severity of Hepatitis C Recurrence and Survival After Liver Transplantation** *DIGESTIVE DISEASES AND SCIENCES*
Michaels, A. J., Dhanasekaran, R., Foley, D. P., Alkhasawneh, A., Dixon, L., Soldevila-Pico, C., Morelli, G., Cabrera, R., Clark, V. C., Firpi, R. J.
2013; 58 (5): 1403-1409
- **Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma** *ONCOLOGY REPORTS*
Dhanasekaran, R., Hemming, A. W., Zendejas, I., George, T., Nelson, D. R., Soldevila-Pico, C., Firpi, R. J., Morelli, G., Clark, V., Cabrera, R.
2013; 29 (4): 1259-1267
- **Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma** *JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY*
Prajapati, H. J., Dhanasekaran, R., El-Rayes, B. F., Kauh, J. S., Maithe, S. K., Chen, Z., Kim, H. S.
2013; 24 (3): 307-315
- **Chinese skullcap in move free arthritis supplement causes drug induced liver injury and pulmonary infiltrates.** *Case reports in hepatology*
Dhanasekaran, R., Owens, V., Sanchez, W.
2013; 2013: 965092-?
- **Liver Test Results Do Not Identify Liver Disease in Adults With alpha(1)-Antitrypsin Deficiency** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Clark, V. C., Dhanasekaran, R., Brantly, M., Rouhani, F., Schreck, P., Nelson, D. R.
2012; 10 (11): 1278-1283
- **Incidentally discovered HCC (iHCC) in explant liver- Clinical and histopathologic features and outcome** *63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease (AASLD)*
Dhanasekaran, R., Pannu, D. S., Ismail, B., Zendejas, I., Firpi, R. L., Soldevila-Pico, C., Morelli, G., Clark, V. C., Suman, A., Nelson, D. R., Cabrera, R.
WILEY-BLACKWELL.2012: 476A–477A
- **The Impact of Pre transplant Transarterial Therapy in Hepatocellular Carcinoma** *63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease (AASLD)*
Pannu, D. S., Dhanasekaran, R., Bahaaeldeen, I., Zendejas, I., Firpi, R. J., Soldevila-Pico, C., Morelli, G., Clark, V. C., Nelson, D. R., Suman, A., Cabrera, R.
WILEY-BLACKWELL.2012: 458A–459A
- **Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma on Long-term Outcomes After Liver Transplantation** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Cabrera, R., Dhanasekaran, R., Caridi, J., Clark, V., Morelli, G., Soldevila-Pico, C., Magglio, J., Nelson, D., Firpi, R. J.
2012; 35 (4): 345-350
- **Prognostic Value of F-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Predicting Survival in Patients with Unresectable Metastatic Melanoma to the Liver Undergoing Yttrium-90 Radioembolization** *JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY*
Piduru, S. M., Schuster, D. M., Barron, B. J., Dhanasekaran, R., Lawson, D. H., Kim, H. S.
2012; 23 (7): 943-948
- **Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy** *PATHOLOGY RESEARCH AND PRACTICE*
Farris, A. B., Dursun, N., Dhanasekaran, R., Coban, I., McIntosh, E. B., Adsay, N. V., Kim, H. S.
2012; 208 (1): 15-21
- **Rare case of adult undifferentiated (embryonal) sarcoma of the liver treated with liver transplantation: excellent long-term survival.** *Case reports in hepatology*
Dhanasekaran, R., Hemming, A., Salazar, E., Cabrera, R.
2012; 2012: 519741-?
- **Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics.** *Hepatic medicine : evidence and research*

Dhanasekaran, R., Limaye, A., Cabrera, R.
2012; 4: 19-37

- **KLATSKIN TUMOR- CLINICAL OUTCOME AND PROGNOSTIC FACTORS**
Dhanasekaran, R., Hemming, A. W., Nelson, D. R., Soldevila-Pico, C., Firpi, R. J., Morelli, G., Clark, V. C., George, T. J., Cabrera, R.
WILEY-BLACKWELL.2011: 1372A
- **ALT ABNORMALITIES IN ADULTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY** *46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)*
Clark, V., Brantly, M., Dhanasekaran, R., Schreck, P., Rouhani, F., Nelson, D.
ELSEVIER SCIENCE BV.2011: S354-S354
- **PANCRELIPASE FOR PANCREATIC DISORDERS: AN UPDATE** *DRUGS OF TODAY*
Dhanasekaran, R., Toskes, P. P.
2010; 46 (11): 855-866
- **THE IMPACT OF PRESERVATION INJURY ON ACCELERATED HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION** *61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*
Michaels, A., Dhanasekaran, R., Alkhasawneh, A., Dixon, L., Soldevila-Pico, C., Morelli, G. (., Cabrera, R., Clark, V., Nelson, D. R., Firpi, R. J.
WILEY-BLACKWELL.2010: 320A-320A
- **MULTIVARIATE SURVIVAL ANALYSIS OF PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA TREATED WITH DOXORUBICIN DRUG ELUTING BEADS TRANSCATHETER CHEMOEMBOLIZATION** *61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*
Dhanasekaran, R., Rafi, S., El-Rayes, B. F., Kauh, J. S., Kooby, D. A., Kim, H. S.
WILEY-BLACKWELL.2010: 1165A-1166A
- **The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma** *JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY*
Dhanasekaran, R., Khanna, V., Kooby, D. A., Spivey, J. R., Parekh, S., Knechtel, S. J., Carew, J. D., Kauh, J. S., Kim, H. S.
2010; 21 (8): 1197-1204
- **Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades.**
Dhanasekaran, R., McIntosh, E. B., Kauh, J. S., Kooby, D. A., El-rayes, B. F., Kim, H. S.
AMER SOC CLINICAL ONCOLOGY.2010
- **Chemoembolization with doxorubicin drug-eluting beads for unresectable hepatocellular carcinoma with portal vein thrombosis**
McIntosh, E. B., Dhanasekaran, R., Kauh, J. S., El-rayes, B. F., Kooby, D. A., Williams, R. S., Kim, H. S.
AMER SOC CLINICAL ONCOLOGY.2010
- **Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin**
Farris, A. B., Dhanasekaran, R., Dursun, N., Coban, I., McIntosh, E. B., Adsay, V., Kim, H. S.
AMER SOC CLINICAL ONCOLOGY.2010
- **Comparison of Conventional Transarterial Chemoembolization (TACE) and Chemoembolization With Doxorubicin Drug Eluting Beads (DEB) for Unresectable Hepatocellular Carcinoma (HCC)** *JOURNAL OF SURGICAL ONCOLOGY*
Dhanasekaran, R., Kooby, D. A., Staley, C. A., Kauh, J. S., Khanna, V., Kim, H. S.
2010; 101 (6): 476-480
- **Influence of Patient Age on Short Term and Long Term Survival After Tips**
Dhanasekaran, R., Parekh, S., Kim, H. S.
W B SAUNDERS CO-ELSEVIER INC.2010: S817
- **Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study** *HPB*
Dhanasekaran, R., Kooby, D. A., Staley, C. A., Kauh, J. S., Khanna, V., Kim, H. S.
2010; 12 (3): 174-180
- **Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Refractory Hepatic Hydrothorax in Patients With Cirrhosis** *AMERICAN JOURNAL OF GASTROENTEROLOGY*

Dhanasekaran, R., West, J. K., Gonzales, P. C., Subramanian, R., Parekh, S., Spivey, J. R., Martin, L. G., Kim, H. S.
2010; 105 (3): 635-641

- **PREDICTORS OF EARLY MORTALITY AFTER TRAN-SJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS (TIPS)** *60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*
Dhanasekaran, R., Gonzales, P. C., West, J., Subramanian, R., Parekh, S., Spivey, J. R., Reshamwala, P., Martin, L. G., Kim, H. S.
WILEY-BLACKWELL.2009: 436A-437A
- **Drug eluting beads versus conventional TACE for unresectable hepatocellular carcinoma: Survival benefits and safety** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Dhanasekaran, R., Kooby, D. A., Staley, C. A., Kauh, J. S., Kim, H. S.
AMER SOC CLINICAL ONCOLOGY.2009
- **Locoregional therapies as a bridge to transplant in patients with hepatocellular carcinoma** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Sakaria, S. S., Dhanasekaran, R., Pankonin, M., Parekh, S., Kauh, J. S., Kim, H. S.
AMER SOC CLINICAL ONCOLOGY.2009
- **High-risk factors affecting survival after transcatheter therapy with doxorubicin-eluting beads for unresectable hepatocellular carcinoma** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
West, J. K., Dhanasekaran, R., Kooby, D. A., Staley, C. A., Kauh, J., Kim, H. S.
AMER SOC CLINICAL ONCOLOGY.2009
- **Radioembolization for unresectable chemorefractory hepatic metastases - Safety and efficacy**
Dhanasekaran, R., Kooby, D., Staley, C., Kauh, J., Montilla-Soler, J., Barron, B., Kim, H.
SOC NUCLEAR MEDICINE INC.2009
- **Chemoembolization Combined with Radiofrequency Ablation for Hepato cellular Carcinoma; Survival Benefits and Tumor Treatment Response**
Dhanasekaran, R., Khanna, Kooby, D., Delman, K., Staley, C., Kauh, J., Carew, J., Kim, H.
AMER ROENTGEN RAY SOC.2009
- **Liver transplantation for hepatocellular carcinoma** *BRITISH JOURNAL OF SURGERY*
Lo, C. M., Fan, S. T.
2004; 91 (2): 131-133

PRESENTATIONS

- Short-term and Long-term Survival after Transjugular Intrahepatic Portosystemic Shunt Creation - 95th Scientific Assembly and Annual Meeting of the Radiological Society of the Radiological Society of North America (11/2009)
- Refractory HepaticHydrothorax Survival after Transjugular Intrahepatic Portosystemic Shunt (TIPS) - 95th Scientific Assembly and Annual Meeting of the Radiological Society of the Radiological Society of North America (11/2009)
- Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Patients Awaiting Transplant - 95th Scientific Assembly and Annual Meeting of the Radiological Society of the Radiological Society of North America (11/2009)
- Efficacy of percutaneous intervention for biliary stricture in pediatric liver transplant patients - Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (9/2009)
- Biliary complications in pediatric liver transplant patients: a 12 year single institution experience - Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (9/2009)
- Transcatheter Therapy for Symptomatic Unresectablehepatic Metastases of Neuroendocrine Tumors - Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (9/2009)
- Evaluation of prognostic factors in the development of biliary complications in pediatric liver transplant patients - The Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (9/2009)
- Efficacy of percutaneous intervention for biliary leak in pediatric liver transplant patients. - Annual Meeting of the Cardiovascular and Interventional Radiological Society of Europe (9/2009)
- Chemoembolization Combined with Radiofrequency Ablation for Hepato cellular Carcinoma; Survival Benefits and Tumor Treatment Response. - 109th Annual Scientific Meeting of the American Roentgen Ray Society (5/1964)
- Locoregional Therapies as a Bridge to Transplant in Patients with Hepatocellular Carcinoma - American Society of Clinical Oncology (6/2009)
- High Risk Factors Affecting Survival After Transcatheter Therapy with Doxorubicin Eluting Beads for Unresectable Hepatocellular Carcinoma - American Society of Clinical Oncology (6/2009)

- Drug eluting beads versus conventional TACE for unresectable hepatocellular carcinoma: Survival benefits and safety - American Society of Clinical Oncology (6/27/2009)
- Radioembolization vs. Chemoembolization for unresectable Neuroendocrine tumor hepatic metastase - Society of Nuclear Medicine (1/2009)
- Radioembolization for unresectable chemorefractory hepatic metastases-Safety and efficacy - Society of Nuclear Medicine (6/2009)
- Predictors of Early Mortality After Transjugular Intrahepatic Portosystemic Shunts (TIPS) - AASLD Liver Meeting (2009)
- Locoregional Therapies as a Bridge to Transplant in Patients with Hepatocellular Carcinoma - AASLD Liver Meeting (2009)
- Risk Factors for Early Mortality After Transcatheter Therapy for HCC - Society of Interventional Radiology Conference (2009)
- 191 Transcatheter Therapy for Unresectable HCC: Prognostic Factors for Survival - Society of Interventional Radiology Conference (2/2009)
- 191Transcatheter Therapy for Unresectable HCC: Prognostic Factors for Survival - Society of Interventional Radiology Conference (2/2009)
- Survival Benefits of Yttrium-90 Radioembolization (SIR-Spheres) for Hepatic Metastasis from Melanoma: Preliminary Study. - Society of Interventional Radiology Conference (2/2009)
- Yttrium-90 Radioembolization (SIR-Spheres) for Cholangiocarcinoma: Preliminary Study - Society of Interventional Radiology Conference (2/2009)
- Comparison of Survival Benefits of Conventional TACE, Precision TACE(Drug Eluting Beads with Doxorubicin) and Yttrium-90 Radioembolization (SIR-Spheres) for Unresectable HCC - Society of Interventional Radiology Conference (2/2009)
- Impact of Portal Vein Thrombosis on Survival After Transcatheter Therapy for Unresectable HCC - Society of Interventional Radiology Conference (2/2009)
- Role of Transcatheter Therapy as a Bridge to Liver Transplant for HCC Patient - Society of Interventional Radiology Conference (2/2009)
- A rare case of recurrent meningitis in a patient with SLE - American College of Physicians Conference, Florida Chapter (9/2009)
- Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) afterdrug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin - American Society of Clinical Oncology (5/2010)
- Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decade - American Society of Clinical Oncology (5/2010)
- Chemoembolization with doxorubicin drug-eluting beads for unresectable hepatocellular carcinoma with portal vein thrombosis - American Society of Clinical Oncology (5/2010)
- Hepatocellular carcinoma recurrences after orthotopic liver transplantation and locoregional therapy - Society of Interventional Radiology Conference (2/2010)
- Survival after transjugular intrahepatic portosystemic shunts -covered vs. uncovered stents - Society of Interventional Radiology Conference (2/2010)
- Transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites - Society of Interventional Radiology Conference (2/2010)
- Tumorigenesis and angiogenesis factors in hepatocellular carcinoma after locoregional therapy - Society of Interventional Radiology Conference (2/2010)
- 100-300% drug eluted bead with 100mg doxorubicin transcatheter chemoembolization for HCC; initial experience - Society of Interventional Radiology Conference (2/2010)
- Does Hepatic Preservation Injury Predict Severity of Hepatitis C Recurrence after Liver Transplantation? - AASLD Liver Meeting 2010 (11/2010)
- Multivariate Survival Analysis of Predictive Factors of Hepatocellular Carcinoma Treated with Doxorubicin Drug Eluting Beads Transcatheter Chemoembolization - AASLD Liver Meeting 2010 (11/2010)
- The impact of transarterial therapy in recurrent hepatocellular carcinoma after liver transplant - AASLD Liver Meeting (11/2010)
- Chest pain in a young adult-more than one cause? - American College of Physicians, Florida Chapter (3/2010)
- Tumors do not read text books! - American College of Physicians Conference, Florida Chapter (11/2010)
- A sustained viral response dramatically improves survival in patients with Hepatitis C infection after liver transplant - European Association for the Study of Liver Diseases (4/2010)
- Alt Abnormalities InAdults With Alpha-1 Antitrypsin Deficiency - European Association for the Study of Liver Diseases (4/2010)
- Influence of patient age on short term and long term survival after TIPS - Digestive Disease Week (5/2010)
- Treatment Outcomes and Prognostic Factors for Intrahepatic Cholangiocarcinoma Single Center Experience - Digestive Disease Week 2011 (5/2011)
- Transjugular intrahepatic portosystemic shunt (TIPS): Time trends in etiology of cirrhosis, indications, and survival. - Society of Interventional Radiology Conference (3/2011)
- Survival outcomes of doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE) for advanced hepatocellular carcinoma (HCC) - Society of Interventional Radiology Conference (3/2011)
- The Impact of Pre transplant Transarterial Therapy in Hepatocellular Carcinoma - AASLD Liver Meeting 2012 (11/2012)

- Incidentally discovered HCC (iHCC) in explant liver-Clinical and histopathologic features and outcome - AASLD Liver Meeting 2012 (11/2012)
- Rate and Predictors of Progression and Mortality in a Large Population Based Cohort of Barrett's esophagus - Digestive Disease Week 2013 (5/2013)
- Is NASH Related HCC Different From HCC Related to Other Causes - Digestive Disease Week 2013 (5/2013)
- Analysis of Paired Biopsies to Assess Progression of Fibrosis in Patients Treated for Post-Transplant Hepatitis C Recurrence - Digestive Disease Week 2013 (5/2013)
- Comparing Internet Search Patterns for Gastroenterological Diagnoses to Physician Visit Data - Annual Meeting American College of Gastroenterology (10/2013)
- Internet Search Patterns for Gastroenterological Symptoms and the Relationship to Physician Visits - Annual Meeting American College of Gastroenterology 2013 (10/2013)
- Validation of immunohistochemistry-based classification of hepatic adenomas: Different subtype distribution in a large US experience - AASLD Liver Meeting (11/2013)
- Clinical outcomes after resection in patients with NASH-related HCC - EASL Liver Meeting (4/2014)
- Bridging locoregional therapy enhances long-term survivals in hepatocellular carcinoma patients listed for liver transplant within the milan criteria: a 15-year experience - SIR Interventional Radiology Meeting (3/2014)
- Clinicopathologic factors predicting hepatocellular carcinoma recurrence in patients receiving bridging locoregional therapy for orthotopic liver transplantation: a 15-year experience - SIR Interventional Radiology Meeting (3/2014)
- Thorgeirsson S, Roberts LR. Sulfatase2 (SULF2) Promotes Angiogenesis in Hepatocellular Carcinoma Partly Through the TGF β 1/Periostin Signaling Pathway. - DDW 2014 (5/2014)
- Female Gender Associated With Less Aggressive Tumor Phenotype and Better Survival in HCC. - DDW 2014 (5/2014)
- Activation of the TGF β /SMAD Pathway Underlies a Novel Tumor Promoting Role of Sulfatase1 in Hepatocellular Carcinoma - AASLD 2014 (11/2014)
- A potential role for type XVIII collagen as a suppressor of hepatocellular carcinoma - AASLD 2014 (11/2014)
- Undiagnosed Nonalcoholic Steatohepatitis (NASH) is Responsible for a Significant Proportion of Cryptogenic Hepatocellular Carcinoma (HCC) - DDW 2015 (5/2015)
- Comparative Efficacy of Transarterial Radioembolization (TARE) Versus Chemotherapy or Best Supportive Care for Unresectable Intrahepatic Cholangiocarcinoma (iCCA) - DDW 2015 (5/2015)
- Next Generation Sequencing and Pathway Analysis Reveals Frequent Activation of the PI3-K/AKT Pathway in Gallbladder Cancer: Potential for Targeted Therapy - DDW 2015 (5/2015)
- Multi-platform analysis of Telomerase Reverse Transcriptase (TERT) gene alterations in Hepatocellular Carcinoma (HCC) - AASLD 2015 (11/2015)
- Somatic Mutational Analysis by Next Generation RNA Sequencing Reveals Frequent Mutation of Chromatin and Chromosome Remodeling Genes in Gallbladder Cancer - AASLD 2015 (11/2015)
- Differences in Hepatocellular Carcinoma Incidence and Survival Rates among Asian Mono-Ethnicities. - AASLD 2016 (11/2016)
- The Use of HCV Positive Donors in HCV Negative Liver Transplant Recipients - AASLD 2016 (11/2016)